

TABLE OF CONTENTS

1.	Overview of LanthaScreen™ Cellular Assay Technology	1
2.	Materials Supplied	2
3.	Materials Required, but Not Supplied	2
4.	Cell Culture Conditions	3
4.1	Media Required	3
4.2	Detailed Cell Handling Procedures	3
5.	Assay Procedure	5
5.1	Quick Reference Guide	5
5.2	Detailed Assay Protocol	6
5.3	Detection	8
6.	Representative Data	9
8.	References	10
9.	Purchaser Notification	10

1. Overview of LanthaScreen™ Cellular Assay Technology

Time-resolved FRET (TR-FRET) has been recognized as a method to overcome interfering signals from compounds in high-throughput screening applications. Similar to standard FRET-based assays, TR-FRET relies on the proximity dependent energy transfer between an excited donor fluorophore and a suitable acceptor fluorophore, which can be detected by an increased emission from the acceptor molecule. Invitrogen's LanthaScreen™ TR-FRET technology uses a long lifetime terbium chelate (Tb) fluorophore as a donor species. The majority of fluorophores possess excited-state lifetimes on the order of nanoseconds. In contrast, terbium fluorophores display extended excited state lifetimes on the range of milliseconds. This unique feature allows the measurement of FRET between interacting donor and acceptor molecules after an extended time delay, typically 50–100 microseconds after excitation by a flash lamp excitation source. This delay overcomes interference caused by such things as autofluorescent compounds and precipitate induced light scatter. A complete guide to commonly asked questions and answers regarding LanthaScreen™ technology can be found at www.invitrogen.com/lanthascreen.

The LanthaScreen™ GFP cellular assays represent a unique and sensitive way to utilize TR-FRET technology for the interrogation of target-specific phosphorylation events within endogenous signal transduction pathways. By expressing specific target proteins as fusions with green fluorescent protein (GFP, a suitable TR-FRET acceptor for the excited-state Tb fluorophore) in living cells, modification-specific antibodies labeled with Tb can be used to detect stimulus-induced post-translational modifications in a lysed-cell assay format.

2. Materials Supplied

Cell Line Name:	LanthaScreen™ STAT5 TF-1
Description:	LanthaScreen™ STAT5 TF-1 cells contain a stably integrated expression vector encoding GFP-STAT5a fusion under control of a CMV promoter. The GFP-STAT5a DNA expression construct was introduced into TF-1 cells using lentiviral transduction, followed by selection with Blasticidin. This cell line is a clonal population isolated by flow cytometry using GFP fluorescence as sorting marker.
Catalog Number:	K1598
Shipping Condition:	Dry Ice
Storage Condition:	Liquid nitrogen. Immediately upon receipt, cells must be stored in liquid nitrogen or thawed for immediate use. Cells stored at –80°C can quickly lose viability.
Quantity:	~5,000,000 (5 × 10 ⁶ cells/ml)
Application:	Detection of agonists/antagonists of the JAK2/STAT5 signaling pathway.
Growth Properties:	Suspension
Cell Phenotype:	Lymphoblast
Selection Marker:	Blasticidin (5 µg/ml)
Vector Used:	pLenti- <i>bsd</i> /EmGFP-STAT5 Vector
Mycoplasma Testing:	Negative
BioSafety Level:	1

3. Materials Required, but Not Supplied

Media/Reagents	Recommended Source	Part #
Recovery™ Cell Culture Freezing Medium	Invitrogen	12648-010
RPMI 1640 with GlutaMAX™	Invitrogen	72400-047
Fetal bovine serum (FBS), dialyzed, tissue-culture grade (DO NOT SUBSTITUTE!)	Invitrogen	26400-044
Opti-MEM® I	Invitrogen	11058-021
Fetal Bovine Serum (Charcoal/Dextran-Treated)	Invitrogen	12676-029
Nonessential amino acids (NEAA)	Invitrogen	11140-050
Sodium Pyruvate	Invitrogen	11360-070
Penicillin/Streptomycin (antibiotic)	Invitrogen	15140-122
Blasticidin (antibiotic)	Invitrogen	R210-01
LanthaScreen™ Tb-anti-Mouse Antibody	Invitrogen	PV3766 or PV3767
Anti-STAT5 A/B [pTyr 694/699] Antibody	Invitrogen	PV5262 or PV5263
Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF)	Invitrogen	PHC2011
Lysis buffer	(see Section 5.2.4)	
Protease Inhibitor mix	SIGMA Aldrich	P8340
Phosphatase Inhibitor mix	SIGMA Aldrich	P2850
Recovery™ Cell Culture Freezing Medium	Invitrogen	12648-010
RPMI 1640 with GlutaMAX™	Invitrogen	72400-047
Consumables	Recommended Source	Part #
White tissue culture treated, 384-well assay plates	Corning Life Sciences	3570
Equipment	Recommended Source	
Fluorescence plate reader with top-read and TR-FRET capability	Various	
Filters, if required for plate reader (see Section 5.3)	Chroma Technology Corp.	

For Technical Support for this or other Invitrogen Discovery Sciences Products, dial 760 603 7200, select option 3, extension 40266
For information on frequently asked questions regarding the LanthaScreen™ technology, please go to www.invitrogen.com/lanthascreen

4. Cell Culture Conditions

4.1 Media Required

Component	Growth Medium	Assay Medium	Freezing Medium	Thaw Medium
RPMI 1640 with GlutaMAX™	500 ml (90%)	—	—	500 ml (90%)
Opti-MEM® I (without Phenol Red)	—	500 ml (99.5%)	—	—
Dialyzed FBS	50 ml (10%)	—	—	50 ml (10%)
Charcoal / Dextran stripped FBS	—	2.5 ml (0.5%)	—	—
NEAA	5 ml (0.1 mM)	5 ml (0.1 mM)	—	5 ml (0.1 mM)
Penicillin (antibiotic)	5 ml (100 U/ml)	5 ml (100 U/ml)	—	5 ml (100 U/ml)
Streptomycin (antibiotic)	5 ml (100 µg/ml)	5 ml (100 µg/ml)	—	5 ml (100 µg/ml)
Sodium Pyruvate	5 ml (1 mM)	5 ml (1 mM)	—	5 ml (1 mM)
Blasticidin (antibiotic)	5 µg/ml	—	—	—
GM-CSF	2 ng/ml	—	—	2 ng/ml
Recovery™ Cell Culture Freezing Medium	—	—	100%	—

Note: Unless otherwise stated, have all media and solutions at least at room temperature (we recommend 37°C for optimal performance) before adding them to the cells.

4.2 Detailed Cell Handling Procedures

4.2.1 Thawing Method

- Place 14 ml of Thaw Medium (without Blasticidin) into a T75 flask.
- Place the flask in a humidified 37°C/5% CO₂ incubator for 15 minutes to allow medium to equilibrate to the proper pH and temperature.
- Remove the vial of cells to be thawed from liquid nitrogen and thaw rapidly by placing at 37°C in a water bath with gentle agitation for 1–2 minutes. Do not submerge vial in water.
- Decontaminate the vial by wiping with 70% ethanol before opening in a Class II biological safety cabinet.
- Transfer the vial contents to a sterile 15-ml conical tube.
- Add 10 ml of Thaw Medium (without Blasticidin) drop-wise into the cell suspension.
- Centrifuge cells at 200 × *g* for 5 minutes.
- Aspirate supernatant and resuspend the cell pellet in 1 ml of fresh Thaw Medium (without Blasticidin).
- Transfer contents to the T75 tissue culture flask containing pre-equilibrated Thaw Medium (without Blasticidin) and place flask in a humidified 37°C/5% CO₂ incubator.
- Switch to passaging cells in Growth Medium with Blasticidin once cells appear to be growing at consistent rates for the given background. See **Section 4.2.4** for special considerations.

4.2.2 Propagation Method

1. Cells should be passaged or fed at least twice a week. Cells should be maintained at a density between 5×10^4 and 1×10^6 cells/ml. Do not allow cells to exceed a density of 1×10^6 cells/ml
2. To passage cells, centrifuge the desired amount of cells suspension and resuspend with growth medium at a density of approximately 200,000 cells/ml.

4.2.3 Freezing Method

1. Harvest and count the cells, then spin cells down and resuspend in 4°C Recovery™ Cell Culture Freezing Medium at a density of 5×10^6 cells/ml.
2. Dispense 1.0-ml aliquots into cryogenic vials.
3. Place in an insulated container for slow cooling and store overnight at -80°C .
4. Transfer to liquid nitrogen the next day for storage.

4.2.4 Special Considerations for working with this Cell Line

1. This cell line is a clonal population isolated by Fluorescence Activated Cell Sorting (FACs). Assay performance can be expected to depend upon use of the specified media as responsive cells have been chosen based on these formulations.
2. For additional information about the TF-1 cellular background please contact Technical Support at 1-760-603-7200, select option 3 and enter extension 40266.
3. This cell line is tested to be compatible with Corning tissue culture-treated plates (3570) and may not be suitable for use with other plates.
4. This cell line is Blasticidin resistant.

5. Assay Procedure

The following instructions outline the recommended procedure for monitoring GM-CSF-induced phosphorylation of GFP-STAT5 using TR-FRET as the readout.

Note:

- We recommend using white, tissue-culture-treated, 384-well assay plates with low fluorescence background.
- Some solvents may affect assay performance. Assess the effect of a test compound solvent before screening. This cell line has been qualified for DMSO tolerance up to 1%. See validation packet at www.invitrogen.com/lanthascreen for the assay performance of this cell line in the presence of various DMSO concentrations. The cell stimulation described below is carried out in the presence of 0.1% DMSO to simulate the effect that a test compound solvent might have on the assay. If you use other solvents and/or solvent concentrations, change the following assay conditions and optimize appropriately.

5.1 Quick Reference Guide

For more detailed protocol information, see **Section 5.2**.

Agonist Assay Quick Reference Guide

	Unstimulated Wells	Stimulated Wells (Positive control Agonist)	Cell-free Wells	Test Compound Wells
Step 1 Starve cells	Starve cells in flask for 16–20 hours in low-serum assay medium without GM-CSF			
Step 2 Prepare lysis buffer	Before stimulation of the cells, prepare a suitable volume of complete lysis buffer by adding the necessary protease/phosphatase inhibitors and detection antibodies to the incomplete lysis buffer.			
Step 3 Plate cells	16 µl cells in Assay Medium (100,000 cells/well)	16 µl cells in Assay Medium (100,000 cells/well)	16 µl Assay Medium (no cells)	16 µl cells in Assay Medium (100,000 cells/well)
Step 4 Add Agonist or Test Compounds	4 µl Assay Medium with 0.5% DMSO	4 µl 5X GM-CSF in Assay Medium with 0.5% DMSO	4 µl Assay Medium with 0.5% DMSO	4 µl 5X Test Compounds in 0.5% DMSO
Step 5 Incubate cells	Incubate in a humidified 37°C/5% CO ₂ incubator for 30 minutes. The optimal stimulation time may vary depending on the agonist.			
Step 6 Lyse Cells	Add 15 µl/well of complete lysis buffer including detection antibodies			
Step 7 Equilibrate Reaction	2 hours at room temperature			
Step 8 Read Plate	See Section 5.3			

Antagonist Assay Quick Reference Guide

	Unstimulated Wells	Stimulated Wells	Positive Control Compound Wells	Cell-free Wells	Test Compound Wells
Step 1 Starve cells	Starve cells in flask for 16–20 hours in low-serum assay medium without GM-CSF				
Step 2 Prepare lysis buffer	Before stimulation of the cells, prepare a suitable volume of complete lysis buffer by adding the necessary protease/phosphatase inhibitors and detection antibodies to the incomplete lysis buffer.				
Step 3 Plate cells	16 μ l cells in Assay Medium (100,000 cells/well)	16 μ l cells in Assay Medium (100,000 cells/well)	16 μ l cells in Assay Medium (100,000 cells/well)	16 μ l Assay Medium (no cells)	16 μ l cells in Assay Medium (100,000 cells/well)
Step 4 Add Antagonist or Test Compounds	2 μ l Assay Medium with 1% DMSO	2 μ l Assay Medium with 1% DMSO	2 μ l 10X control compound in Assay Medium with 1% DMSO	2 μ l Assay Medium with 1% DMSO	2 μ l 10X test compound in Assay Medium with 1% DMSO
Optional Step:	Incubate plate with Antagonist for 30 minutes before proceeding				
Step 5 Add Agonist	2 μ l Assay Medium	2 μ l 10X GM-CSF in Assay Medium	2 μ l 10X GM-CSF in Assay Medium	2 μ l 10X GM-CSF in Assay Medium	2 μ l 10X GM-CSF in Assay Medium
Step 6 Incubate cells	Incubate in a humidified 37°C/5% CO ₂ incubator for 30 minutes.				
Step 7 Lyse Cells	Add 15 μ l/well of complete lysis buffer including detection antibodies				
Step 8 Equilibrate Reaction	2 hours at room temperature				
Step 9 Read Plate	See Section 5.3				

5.2 Detailed Assay Protocol

Plate layouts and experimental outlines will vary; in screening mode, we recommend using at least three wells for each control: Unstimulated Control, Stimulated Control, and Cell-free Control.

Note: Some solvents may affect assay performance. Assess the effects of solvent before screening.

5.2.1 Precautions

- Work on a dust-free, clean surface.
- If pipetting manually, you may need to centrifuge the plate briefly at room temperature (30 seconds at 14 \times g) after additions to ensure all assay components are on the bottom of the wells.
- Cells should be grown to reach 5×10^5 to 1×10^6 cells/ml. Do not allow cells to exceed 1×10^6 /ml.

5.2.2 Starve Cells

1. Harvest cells from culture in growth medium and resuspend in assay medium at a density of $0.5\text{--}1 \times 10^6$ cells/ml in a tissue culture flask.
2. Starve cells in a 37°C/5% CO₂ incubator for 16–20 hours.

5.2.3 Plate Cells

1. Harvest cells from assay medium and resuspend in assay medium at a density of 6.25×10^6 cells/ml.
2. Plate the cells into white tissue culture treated 384-well plates. Add 16 μ l per well of Assay Medium to the cell-free control wells. Add 16 μ l per well of the cell suspension to Unstimulated and Stimulated wells.
3. After plating, incubate the plates in a 37°C/5% CO₂ incubator.

5.2.4 Prepare Lysis buffer

1. Prepare lysis buffer: 20 mM Tris, pH 7.4, 5 mM EDTA, 5 mM NaF, 150 mM NaCl, 1% NP-40 (or equivalent). This incomplete lysis buffer can be prepared in large batches and stored at -20°C. The complete lysis buffer (consisting of phosphatase / protease inhibitor cocktails as well as the LanthaScreen™ Tb-anti-mouse and anti-STAT5 A/B [pTyr 694/699] antibody) should be prepared on the day of the experiment.
2. Determine the volume of complete lysis buffer needed for the assay (assuming 20 µl/well). Add 1/100 volume of each protease inhibitor and phosphatase inhibitor cocktail to the incomplete lysis buffer. Mix well by inversion several times.
3. Add LanthaScreen™ Tb-anti-mouse antibody to 10 nM final concentration and add Anti-STAT5 A/B [pTyr 694/699] antibody to 5 nM final concentration in the supplemented lysis buffer. Mix gently by inversion several times.
4. Place complete lysis buffer on ice until use.

5.2.5 Agonist Assay Plate Setup

Note: This subsection provides directions for performing an Agonist assay. See **Section 5.2.6** for directions for performing an Antagonist assay.

Note: The positive agonist controls are run at the concentration of GM-CSF that gives the maximum stimulation (top of the dose response curve). We recommend running a dose response curve to determine the optimal concentration (EC₁₀₀) for your GM-CSF solution. See **Section 6** for a representative dose response curve. From this example data, we determined the EC₁₀₀ to be 5 ng/ml or 357 pM.

1. Prepare a stock solution of 0.5% DMSO in Assay Medium.
2. Prepare a 5X stock of each test compound in Assay Medium with 0.5% DMSO (or if the test compound is dissolved in DMSO, make sure the DMSO concentration for the 5X solution is 0.5%).
3. Reconstitute GM-CSF at 10 µg/ml according to the manufacturer's protocol. Avoid repeated freeze thaws or long term storage above -20°C.
4. Prepare a 5X stock of GM-CSF in Assay Medium containing 0.5% DMSO. We recommend running a dose response curve to determine the EC₁₀₀ for your EGF solution. See **Section 6** for a representative curve.
5. Add 4 µl of the stock solution of 0.5% DMSO in Assay Medium to each Unstimulated Control well and Cell-free Control well.
6. Add 4 µl of the 5X stock solution of GM-CSF to each Stimulated Control well.
7. Add 4 µl of each 5X stock of test compound to each Test Compound well.
8. Incubate the Agonist assay plate in a humidified 37°C/5% CO₂ incubator for 30 minutes. Then proceed to **Section 5.2.6**.

5.2.6 Antagonist Assay Plate Setup

Note: This subsection provides directions for performing an Antagonist assay. See **Section 5.2.5** for directions for performing an Agonist assay.

1. Prepare a stock solution of 1% DMSO in Assay Medium.
2. Prepare a 10X stock of each test compound in Assay Medium with 1% DMSO. (Or if the test compound is dissolved in DMSO, prepare a 10X stock of test compound in Assay Medium and make sure the DMSO concentration for the 10X solution is 1.0%).
3. Reconstitute GM-CSF at 10 µg/ml according to the manufacturer's protocol. Avoid repeated freeze/thaw cycles or long-term storage above -20°C.
4. Prepare a 10X stock of GM-CSF in Assay Medium at an EC₈₀ concentration. We recommend running a dose response curve to determine the EC₈₀ for your GM-CSF solution. See **Section 6** for representative data. From this example data, we determined the EC₈₀ to be 1.3 ng/ml or 92.9 pM.
5. Prepare a 10X stock of positive control inhibitor (control antagonist compound) in Assay Medium with 1.0% DMSO. We recommend running a dose response curve to determine the optimal inhibition concentration for the Antagonist solution.
6. Add 2 µl of each 10X stock of test compound to each Test Compound well.

7. Add 2 µl of the stock solution of Assay Medium with 1.0% DMSO to each Stimulated Control well, Unstimulated Control well, and Cell-free Control well.
8. Add 2 µl of the 10X stock of positive control inhibitor to each Positive Control well.
9. If desired, incubate the test compound with the cells in a humidified 37°C/5% CO₂ incubator before proceeding. Typically, a 30-minute incubation is sufficient.
10. Add 2 µl of the 10X EC₈₀ stock solution of GM-CSF prepared in step 4 to each Test Compound well, Stimulated Control well, Antagonist Control well, and Cell-free Control well.
11. Add 2 µl of Assay Medium to each Unstimulated Control well.
12. Incubate the Antagonist assay plate in a humidified 37°C/5% CO₂ incubator for 30 minutes.

5.2.7 Cell Lysis

1. Remove assay plate from the humidified 37°C/5% CO₂ incubator
2. Add 15 µl of complete lysis buffer to each well and cover plate.
3. Incubate covered plate at room temperature for 2 hours.

5.3 Detection

All TR-FRET measurements are to be made at room temperature from the top of the wells, preferably in 384-well, low volume white assay plates with low fluorescence background.

5.3.1 Instrumentation, Filters, and Plates

The data presented in this document were generated using a BMG Pherastar plate reader using the LanthaScreen™ filter block available from BMG. The assay can be performed on a variety of plate readers including those from Tecan. If you are using a LanthaScreen™ GFP Cellular Assay, we do not recommend the use of monochromatic-based instruments, as the sensitivity of these instruments is not sufficient to adequately detect the endogenously expressed GFP fusion proteins. Visit www.invitrogen.com/Lanthascreen or contact Invitrogen Discovery Sciences Technical Support at 800-955-6288 (select option 3 and enter 40266), or email tech_support@invitrogen.com for more information on performing LanthaScreen™ assays on your particular instrument. Recommended filters for the fluorescence plate reader are:

Excitation filter:	337 nm
Donor Emission filter:	490 nm
Acceptor Emission filter:	520 nm
Integration start	100 sec
Integration time	200 sec

5.3.2 Reading an Assay Plate

1. Set the fluorescence plate reader to top / time resolved-read mode.
2. Allow the lamp in the fluorescence plate reader to warm up for at least 10 minutes before making measurements.
3. Use the following filter selections:

	Scan 1	Scan 2
Purpose:	Measure Donor (Terbium) Signal	Measure Acceptor (TR-FRET to GFP) Signal
Excitation filter:	337 nm (30 nm bandwidth)	
Emission filter:	490 nm (10 nm bandwidth)	520 nm (25 nm bandwidth)
Dichroic Mirror	Variable, see above	
Delay Time	100 µs	
Integration Time	200 µs	

4. Calculate the acceptor/donor Emission Ratio (TR-FRET Ratio) for each well, by dividing the acceptor emission values by the donor emission values.

6. Representative Data




Figure 1. Dose response of LanthaScreen™ STAT5 TF-1 cells to GM-CSF. LanthaScreen™ TF-1 STAT5 cells were starved overnight in a flask and treated with GM-CSF over the indicated concentration range in a 384-well format. Cells were incubated for 30 minutes with indicated concentrations of GM-CSF I in the presence of 0.1% DMSO and then lysed in the presence of LanthaScreen™ Tb-anti-Mouse and Anti-STAT5 A/B [pTyr694/699] antibodies for 2 hours. TR-FRET values were obtained using a BMG PHERAstar fluorescence plate reader and the 520/490 ratios were plotted against the concentration of the agonist.

8. References

Roberts MB., *et al*, **High-Throughput Cellular Assays for Regulated Posttranslational Modifications**, (2008) *Anal Biochem.* 2008 Jan 15;372(2):189-97.

9. Purchaser Notification

Limited Use Label License No. 5: Invitrogen Technology

The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Invitrogen Corporation will not assert a claim against the buyer of infringement of patents owned or controlled by Invitrogen Corporation which cover this product based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500. Email: outlicensing@invitrogen.com.

Limited Use Label License No. 51: Blasticidin and the Blasticidin Selection Marker

Blasticidin and the blasticidin resistance gene (*bsd*) are the subject of U.S. Patent No. 5,527,701 sold under patent license for research purposes only. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500.

Use of Genetically Modified Organisms (GMO)

Information for European Customers: The LanthaScreen™ STAT5 TF-1 cell line(s) are genetically modified with the plasmid pLenti-*bsd*/EmGFP-STAT5. As a condition of sale, use of this product must be in accordance with all applicable local legislation and guidelines including EC Directive 90/219/EEC on the contained use of genetically modified organisms.

© 2008, Invitrogen Corporation. All rights reserved. Reproduction forbidden without permission.